Withdrawal from psychostimulants including methamphetamines, cocaine, and nicotine, produced restructuring of brain regions and major increases in functional connectivity, a new mouse study reveals.
PsychLight, a newly developed genetically encoded fluorescent sensor, helped researchers identify a psychedelic compound that acts on beneficial neural pathways to treat psychiatric disorders without the hallucinogenic effect.
Rotigotine, a drug that acts on dopamine transmission, improves cognitive function in patients with mild-to-moderate Alzheimer's disease. While the drug did not help improve memory, it did improve executive function in the frontal lobe and positively impacted the ability of patients to perform activities of daily living.
Researchers have developed a cyclic peptide that can enhance blood-brain barrier penetration.
Dantrolene, a common muscle relaxant, shows promise in the treatment of Alzheimer's disease. Mice administered the drug intranasally had higher concentrations of the medicine in their brains, and for longer periods, than those who received it orally. The drug has been shown to help inhibit or slow the progression of several neurodegenerative diseases.
Alzheimer's patients who used antipsychotics had a 29% increased risk of head injury and a 22% higher risk of TBI compared to others with the neurodegenerative disease who did not use the medications.
Dogs with epilepsy who received cannabidiol as part of a clinical trial had a reduction in the frequency of seizures.
Researchers report, contrary to popular belief, Adderall and other ADHD drugs do not improve cognition in healthy college students. Instead, they may impair cognitive function.
A newly developed experimental drug, that contains similar compounds to those in diabetes medications, slows the progression of Parkinson's in mouse models of the disease, researchers report.
Ketamine may improve brain functions involved in mood regulation, researchers report.